No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: A meta-analysis of randomized controlled trials
Open accessThe DOI matches its Crossref record; 69 of the 70 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND OBJECTIVES: Statins showed mixed results in heart failure (HF) patients. The benefits in major HF outcomes, including all-cause mortality and sudden cardiac death (SCD), have always been discordant across systematic reviews and meta-analyses. We intended to systematically identify and appraise the available evidence that evaluated the effectiveness of statins in clinical outcomes for HF patients. DESIGN: Systematic review and meta-analysis. DATA SOURCES: We searched, until April 28, 2016: Medline, Embase, ISI Web of Science and EBM reviews (Cochrane DSR, ACP journal club, DARE, CCTR, CMR, HTA, and NHSEED), checked clinicaltrials.gov for ongoing trials and manually searched references of included studies. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: We identified 24 randomized clinical trials that evaluated the efficacy of statins for HF patients. All randomized clinical trials were assessed for risk of bias and pooled together in a meta-analysis. Pre-specified outcomes were sudden cardiac death, all-cause mortality, and hospitalization for worsening heart failure. RESULTS: Statins did not reduce sudden cardiac death (SCD) events in HF patients [relative risk (RR) 0.92, 95% confidence interval (CI) 0.70 to 1.21], all-cause mortality [RR 0.88, 95% CI 0.75 to 1.02] but significantly reduced hospitalization for worsening heart failure (HWHF) although modestly [RR 0.79, 95% CI 0.66 to 0.94]. Nevertheless, estimated predictive intervals were insignificant in SCD, all-cause mortality and HWHF [RR, 0.54 to 1.63, 0.64 to 1.19, and 0.54 to 1.15], respectively. An important finding was the possible presence of publication bias, small-study effects and heterogeneity of the trials conducted in HF patients. CONCLUSIONS: Statins do not reduce sudden cardiac death, all-cause mortality, but may slightly decrease hospitalization for worsening heart failure in HF patients. The evaluation of the risk of biases suggested moderate quality of the published results. Until new evidence is available, this study supports the 2013 ACCF/AHA guidelines to not systematically prescribe statins in "only" HF patients, which should help avoid unnecessary polypharmacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









![Fig 10 Efficacy of statins compared with control in heart failure stratified by endpoint (those with against without mortality and/or HWHF) for the prevention of (A) sudden cardiac death (SCD) (B) all-cause mortality, and (C) hospitalization for worsening heart failure (HWHF). [Random-effects model].](https://figures.cochat.ai/paper-figures/cac0e8a037214453a87b9e1eaa0761a4/no-benefits-of-statins-for-sudden-cardiac-death-prevention-in-patients-with-figure-10.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [450]
Experimental — accuracy not yet measuredIn the citing paper
“Results were consistent in the subgroup of patients with a history of MI (81% of all patients) [119,450].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [450]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“Also, we rated the quality of the evidence using a summary of findings table from the GRADE approach [28].”
Method(2008) · Cited by 3,790
Zipes, D. P., & Wellens, H. J. J. (1998) · Circulation · doi:10.1161/01.cir.98.21.2334 · Cited by 2,744
Rosuvastatin in older patients with systolic heart failure
Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706201 · Cited by 1,487 · cited 10×
“The mean age of the three biggest studies (CORONA [13], GISSI-HF [12] and Takano H.”
BackgroundMethodResultInfluentialChemical, pharmacokinetic and pharmacodynamic properties of statins: an update
Schachter, M. (2005) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00299.x · Cited by 1,211 · cited 1×
“Many argued that CORONA [13] and GISSI-HF [12] used a hydrophilic statin (rosuvastatin) that may have a different effectiveness than the predominantly lipophilic statins (atorvastatin, simvastatin, lovastatin, fluvastatin, cerivastatin and pitavastatin)—pravastatin and rosuvastatin are relatively hydrophilic[62].”
BackgroundGISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61240-4 · Cited by 1,106
Sample Size Calculations in Clinical Research
Chow, S.-C., Wang, H., & Shao, J. (2003) · CRC Press eBooks · doi:10.1201/9780203911341 · Cited by 807
The relationship between cholesterol and survival in patients with chronic heart failure
Rauchhaus, M., Clark, A. L., Doehner, W., Davos, C., Bolger, A., Sharma, R., Coats, A. J. S., & Anker, S. D. (2003) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.07.016 · Cited by 444
Node, K., Fujita, M., Kitakaze, M., Hori, M., & Liao, J. K. (2003) · Circulation · doi:10.1161/01.cir.0000084539.58092.de · Cited by 414 · cited 3×
“et al [50] whereas the authors of those small trials stated that no death occurred during the study period.”
BackgroundInfluentialHorwich, T. B., Hamilton, M. A., MacLellan, W. R., & Fonarow, G. C. (2002) · Journal of Cardiac Failure · doi:10.1054/jcaf.2002.0804216 · Cited by 337
(2004) · European Heart Journal · doi:10.1016/j.ehj.2004.06.003 · Cited by 331
Sola, S., Mir, M. Q. S., Khan, B. V., Lerakis, S., & Tandon, N. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.06.088 · Cited by 324 · cited 2×
“[51] 54 63 Stable non-ischaemic HF Non-ischaemic 33 II-IV Strey CH.”
Analysis of human immune responses in quasi-experimental settings: tutorial in biostatistics
Sarkar, R., Ajjampur, S. S., Ward, H. D., Kang, G., & Naumova, E. N. (2012) · BMC Medical Research Methodology · doi:10.1186/1471-2288-12-1 · Cited by 305
Sample Size Calculations in Clinical Research
White, I. (2008) · Journal of the Royal Statistical Society Series A: Statistics in Society · doi:10.1111/j.1467-985x.2008.00538_2.x · Cited by 299
Horwich, T. B., Hamilton, M. A., MacLellan, W. R., & Fonarow, G. C. (2002) · Journal of Cardiac Failure · doi:10.1054/jcaf.2002.126519a · Cited by 279
Clinical Outcomes in Statin Treatment Trials: A Meta-analysis
Ross, S. D., Allen, I. E., Connelly, J. E., Korenblat, B. M., Smith, M. E., Bishop, D., & Luo, D. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.15.1793 · Cited by 217 · cited 1×
“Several previously published meta-analyses [9,11,18,38] evaluated the effects of statins in SCD prevention and reported a decrease but all studies were limited by indirectness as they included different populations, i.”
BackgroundAl‐Gobari, M., El-Khatib, C., Pillon, F., & Gueyffier, F. (2013) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-13-52 · Cited by 169
Self-citationPreiss, D., Campbell, R. T., Murray, H. M., Ford, I., Packard, C. J., Sattar, N., Rahimi, K., Colhoun, H. M., Waters, D. D., LaRosa, J. C., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv072 · Cited by 160 · cited 2×
“Several previously published meta-analyses [9,11,18,38] evaluated the effects of statins in SCD prevention and reported a decrease but all studies were limited by indirectness as they included different populations, i.”
BackgroundAn optimal search filter for retrieving systematic reviews and meta-analyses
Lee, E., Dobbins, M., DeCorby, K., McRae, L., Tirilis, D., & Husson, H. (2012) · BMC Medical Research Methodology · doi:10.1186/1471-2288-12-51 · Cited by 151 · cited 1×
“In a first step, we used a filter [25,26] to search for systematic reviews and meta-analyses and initially excluded individual clinical trials for the purpose of our study.”
MethodA hands-on practical tutorial on performing meta-analysis with Stata
Chaimani, A., Mavridis, D., & Salanti, G. (2014) · Evidence Based Mental Health · doi:10.1136/eb-2014-101967 · Cited by 132
Krum, H., Ashton, E., Reid, C. M., Kalff, V., Rogers, J., Amarena, J., Singh, B., & Tonkin, A. M. (2007) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.09.008 · Cited by 122 · cited 2×
“[46] 62 80 NYHA II-IV, LVEF 35% or 40% Ischaemic,12 29 II-IV”
BackgroundWilczynski, N. L., & Haynes, R. B. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.04.001 · Cited by 120 · cited 1×
“In a first step, we used a filter [25,26] to search for systematic reviews and meta-analyses and initially excluded individual clinical trials for the purpose of our study.”
MethodTousoulis, D., Antoniades, C. A., Vassiliadou, C., Toutouza, M., Pitsavos, C. E., Tentolouris, C. A., Trikas, A. G., & Stefanadis, C. (2005) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2005.03.007 · Cited by 110 · cited 4×
“et al.[29] 69 100 Ischaemic HF, LVEF 35% Ischaemic 25 III-IV Tousoulis D.”
BackgroundMethodInfluentialWojnicz, R., Wilczek, K. L., Nowalany-Kozielska, E., Szyguła‐Jurkiewicz, B., Nowak, J. U., Poloński, L., Dyrbuś, K., Bądziński, A., Mercik, G., Zembala, M., et al. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.09.142 · Cited by 102 · cited 2×
“[55] 2006 74(36/38) Atorvastatin No statin LDL-c 4.”
BackgroundLipinski, M. J., Cauthen, C. A., Biondi‐Zoccai, G., Abbate, A., Vrtovec, B., Khan, B. V., & Vetrovec, G. W. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.07.055 · Cited by 100 · cited 1×
“Moreover, a meta-analysis [63] pooled 10 trials (out of the 24 in our analysis) and showed no benefits for overall non stratified population and concluded for trend toward benefits for atorvastatin at subgroup analysis.”
MethodVrtovec, B., Okrajšek, R., Goličnik, A., Ferjan, M., Starc, V., & Radovančević, B. (2005) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2005.06.439 · Cited by 94 · cited 2×
“[53] 2005 80(40/40) Atorvastatin No statin TC 5.”
BackgroundTousoulis, D., Antoniades, C. A., Bosinakou, E., Kotsopoulou, M., Pitsavos, C. E., Vlachopoulos, C. V., Panagiotakos, D. B., & Stefanadis, C. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.08.037 · Cited by 88
Beneficial effects of statins in patients with non-ischemic heart failure
Laufs, U., Waßmann, S., Schackmann, S., Heeschen, C., B�hm, M., & Nickenig, G. (2004) · Zeitschrift für Kardiologie · doi:10.1007/s00392-004-1005-0 · Cited by 86 · cited 2×
“et al.[47] 2004 15(8/7) Cerivastatin Placebo LDL-c 3.”
BackgroundBleske, B. E., Nicklas, J. M., Bard, R. L., Brook, R. D., Gurbel, P. A., Bliden, K. P., Rajagopalan, S., & Pitt, B. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.06.087 · Cited by 86
Erbs, S., Beck, E. B., Linke, A., Adams, V., Gielen, S., Kränkel, N., Möbius‐Winkler, S., Höllriegel, R., Thiele, H., Hambrecht, R., et al. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.02.019 · Cited by 79 · cited 2×
“[43] 62 76 CHF—Ischaemic HF or DC Ischaemic,28 30 II-III Gissi-HF Investigators [12] 68 77 CHF, No LVEF restriction Ischaemic,40 33 II-IV”
Yamada, T., Node, K., Mine, T., Morita, T., Kioka, H., Tsukamoto, Y., Tamaki, S., Masuda, M., Okuda, K., & Fukunami, M. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.03.027 · Cited by 73 · cited 2×
“[57] 2007 38(19/19) Atorvastatin No statin LDL-c 3.”
The Effects of Atorvastatin (10 mg) on Systemic Inflammation in Heart Failure
Mozaffarian, D., Minami, E., Letterer, R. A., Lawler, R. L., McDonald, G. B., & Levy, W. C. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.07.092 · Cited by 73 · cited 2×
“[49] 51 86 Ambulatory HF, LVEF < 40% Ischaemic, 9 31 II-III Node K.”
Hopper, I., Samuel, R., Hayward, C., Tonkin, A., & Krum, H. (2014) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2014.04.013 · Cited by 67 · cited 1×
“However, 3-hydroxy3-methylglutaryl coenzyme A (HMG-Co A) reductase inhibitors or simply statins are still widely prescribed for HF patients [8].”
BackgroundMeta-Analysis of the Effect of Statins on Mortality in Patients With Preserved Ejection Fraction
Liu, G., Zheng, X., Xu, Y.-L., Ru, J., Hui, R., & Huang, X. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.12.023 · Cited by 67 · cited 1×
“On the other hand, a meta-analysis [33] evaluated statins’ effect in mortality prevention in heart failure with preserved ejection fraction (HFpEF) but included only cohorts and other observational studies.”
BackgroundVrtovec, B., Okrajšek, R., Goličnik, A., Ferjan, M., Starc, V., Schlegel, T. T., & Radovančević, B. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2007.10.013 · Cited by 61 · cited 3×
“[54] 2008 110(55/55) Atorvastatin No statin LDL-c = 2.”
BackgroundStrey, C. H., Young, J. M., Lainchbury, J. H., Frampton, C. M., Nicholls, M. G., Richards, M., & Scott, R. S. (2006) · Heart · doi:10.1136/hrt.2005.082560 · Cited by 60
Total cholesterol levels and mortality risk in nonischemic systolic heart failure
Afsarmanesh, N., Horwich, T. B., & Fonarow, G. C. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.06.015 · Cited by 55
Statins in the Treatment of Chronic Heart Failure: A Systematic Review
van der Harst, P., Voors, A. A., van Gilst, W. H., Böhm, M., & van Veldhuisen, D. J. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030333 · Cited by 55 · cited 1×
“A systematic review [15], published in 2006, stressed on the importance of this research question and pointed out the conflicting and unclear evidence.”
BackgroundLiu, M., Wang, F., Wang, Y., & Jin, R. (2009) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-009-6186-3 · Cited by 54 · cited 2×
“[48] 2009 64(32/32) Atorvastatin Placebo LDL-c 3.”
Rahimi, K., Majoni, W., Merhi, A., & Emberson, J. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs005 · Cited by 54 · cited 1×
“Several previously published meta-analyses [9,11,18,38] evaluated the effects of statins in SCD prevention and reported a decrease but all studies were limited by indirectness as they included different populations, i.”
BackgroundMeta-Analysis of Effect of Statin Treatment on Risk of Sudden Death
Levantesi, G., Scarano, M., Marfisi, R., Borrelli, G., Rutjes, A. W., Silletta, M. G., Tognoni, G., & Marchioli, R. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.07.015 · Cited by 51 · cited 1×
“Several previously published meta-analyses [9,11,18,38] evaluated the effects of statins in SCD prevention and reported a decrease but all studies were limited by indirectness as they included different populations, i.”
BackgroundTakano, H., Mizuma, H., Kuwabara, Y., Sato, Y., Shindo, S., Kotooka, N., Fujimatsu, D., Kobayashi, Y., Inoue, T., Node, K., et al. (2013) · Circulation Journal · doi:10.1253/circj.cj-12-1062 · Cited by 51
Bielecka-Dabrowa, A. M., Goch, J. H., Mikhailidis, D. P., Rysz, J., Maciejewski, M., & Banach, M. (2009) · PubMed · Cited by 48
Abulhul, E., McDonald, K., Martos, R., Phelan, D. M. J., Spiers, P., Hennessy, M., Baugh, J. A., Watson, C. J., O’Loughlin, C., & Ledwidge, M. T. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.11.002 · Cited by 46 · cited 2×
“[40] 2012 56(28/28) Atorvastatin No statin LDL-c = 2.”
Wang, J., Wu, G., Wang, Z., Dai, X.-P., & Li, X. (2013) · Heart Lung and Circulation · doi:10.1016/j.hlc.2013.07.012 · Cited by 39
Hamaad, A., Sosin, M., Lip, G. Y. H., & MacFadyen, R. J. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-2219-8 · Cited by 38 · cited 2×
“[44] 2005 23(13/10) Atorvastatin Placebo TC 3.”
Bonsu, K. O., Reidpath, D. D., & Kadirvelu, A. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6636-z · Cited by 37 · cited 1×
“Based on statin type, two meta-analyses [17,21] included lipophilic statins and stated that they decreased all-cause mortality, cardiovascular death and HWHF.”
BackgroundXie, R., Cui, W., Fan, L., Yang, C., Pei, W., & Lu, J. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.11.030 · Cited by 36
Hong, Y. J., Jeong, M. H., Hyun, D. W., Hur, S., Kim, K. B., Kim, W., Lim, S. Y., Lee, S. H., Hong, S. N., Kang, D. G., et al. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.10.039 · Cited by 35 · cited 3×
“[44] 67 86 Stable systolic HF Ischaemic, 57 31 II-III Hong et al.[58] 61 72 Patients underwent PCI for AMI Ischaemic, 100 31 II-IV Horwich TB.”
BackgroundZhang, L., Zhang, S., Jiang, H., Sun, A., Zou, Y., & Ge, J. (2010) · Clinical Cardiology · doi:10.1002/clc.20821 · Cited by 34
Zhang, L., Zhang, S., Jiang, H., Sun, A., Wang, Y., Zou, Y., Ge, J., & Chen, H. (2010) · Archives of Medical Research · doi:10.1016/j.arcmed.2010.08.009 · Cited by 32
Efficacy of statin therapy in chronic systolic cardiac insufficiency: A meta-analysis
Zhang, S., Zhang, L., Sun, A., Jiang, H., Qian, J., & Ge, J. (2011) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2011.06.003 · Cited by 32 · cited 1×
“Likewise, a meta-analysis [20], included 13 trials, among the 24 trials in our analysis, concluded that statins might have no beneficial effects on all-cause death, cardiovascular death or pump failure and rehospitalization for heart failure in the overall (non-stratified) CHF populations.”
ResultLe, H.-H., El-Khatib, C., Mombled, M., Guitarian, F., Al‐Gobari, M., Fall, M., Janiaud, P., Marchant, I., Cucherat, M., Bejan‐Angoulvant, T., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0145958 · Cited by 32
Self-citationStatins and the Reduction of Sudden Cardiac Death: Antiarrhythmic or Anti-Ischemic Effect?
Beri, A., Contractor, T. A., Khasnis, A. A., & Thakur, R. K. (2010) · American Journal of Cardiovascular Drugs · doi:10.2165/11536690-000000000-00000 · Cited by 30
Effects of Lipophilic Statins for Heart Failure: A Meta-analysis of 13 Randomised Controlled Trials
Liu, G., Zheng, X., Xu, Y.-L., Lü, J., Hui, R., & Huang, X. (2014) · Heart Lung and Circulation · doi:10.1016/j.hlc.2014.05.005 · Cited by 30 · cited 1×
“Based on statin type, two meta-analyses [17,21] included lipophilic statins and stated that they decreased all-cause mortality, cardiovascular death and HWHF.”
BackgroundXu, M.-W., Yuan, G., & Wei, F. (2010) · Archives of Medical Science · doi:10.5114/aoms.2010.19293 · Cited by 23 · cited 1×
“Such result was quite similar to a study [22] which excluded both CORONA [13] and GISSI-HF [12] for no apparent reason.”
ResultHorwich, T. B., Middlekauff, H. R., MacLellan, W. R., & Fonarow, G. C. (2011) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2011.07.008 · Cited by 21 · cited 2×
“[45] 2011 26(14/12) Atorvastatin Placebo LDL-c 2.”
Takagi, H., & Umemoto, T. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.11.079 · Cited by 16
Deo, S. V., Rababa’h, A. M., Altarabsheh, S. E., Lim, J. Y., Cho, Y. H., & Park, S. J. (2014) · Heart Lung and Circulation · doi:10.1016/j.hlc.2014.04.007 · Cited by 12 · cited 1×
“Similarly, a study [34] reported statin benefits in non-ischaemic cardiomyopathy and included two observational studies and ad-hoc analysis of 4 RCTs of which 2 were beta-blockers’ trials and so are not immune to bias.”
BackgroundThe use of statins in patients with heart failure: more questions than answers.
Westman, P. C., & Lipinski, M. J. (2015) · PubMed · doi:10.3978/j.issn.2072-1439.2015.10.47 · Cited by 9 · cited 1×
“Though, such benefits are still insufficient to the current management need as almost half of HF patients die within 5 years after initial diagnosis and half of the mortality is attributed to sudden cardiac death (SCD) [5,6].”
BackgroundTakagi, H., & Umemoto, T. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.09.065 · Cited by 6 · cited 1×
“Of note, two studies [36,39] directly compared atorvastatin (lipophilic statin) to rosuvastatin (hydrophilic statin) but for surrogate endpoints like C-reactive protein and hence did not evaluate any clinical outcomes with a similar output to Lei Zhang et al.”
ResultAre statins beneficial for chronic heart failure? First update
Rain, C., & Gabriel Rada, G. (2017) · Medwave · doi:10.5867/medwave.2017.6853 · Cited by 4
Li, K. (2015) · Medical Science Monitor · doi:10.12659/msm.893681 · Cited by 3
Bias in the Evaluation of Effects of Statins on Mortality in Patients with Heart Failure
White, J., & Stewart, R. (2014) · Heart Lung and Circulation · doi:10.1016/j.hlc.2014.04.133 · Cited by 3 · cited 1×
“The study had a biased result as authors lumped together randomized clinical trials (RCTs) with non-causal observational studies [61] with a high heterogeneity (I(2) = 90%).”
BackgroundDuBroff, R. J. (2016) · Preventive Medicine · doi:10.1016/j.ypmed.2016.01.004 · Cited by 2
Bonsu, K. O., Kadirvelu, A., & Reidpath, D. D. (2015) · Heart Lung and Circulation · doi:10.1016/j.hlc.2015.06.237 · Cited by 2
Review: Statins do not reduce mortality in patients with heart failure
Granger, C. B., & Patel, C. B. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-8-201004200-02006 · Cited by 1 · cited 1×
“Although one cannot exclude that different statins would have different effects on HF outcomes, the hypothesis of differences among statins does not seem to be biologically plausible [16].”
Are statins beneficial for chronic heart failure?
Carmen Rain, M., & Gabriel Rada, G. (2015) · Medwave · doi:10.5867/medwave.2015.04.6140 · Cited by 1
Research works printed but not linked: 2
- Lipinski MJ, Cauthen CA, Biondi-Zoccai GG, Abbate A, Vrtovec B, Khan BV, et al Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure. American Journal of Cardiology. 2009; 104(12): 1708– 16. 10.1016/j.amjcard.2009.07.055 19962481 · DOI
- Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination; c2014. Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure; 2009 [cited 2016 Jun 22]. Available from: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0027479/.
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Metadata
- Authors
- Al-Gobari, M., Le, H.-H., Fall, M., Gueyffier, F., & Burnand, B.
- Affiliations
- Lyon 1 Université (FR)
- Centre Hospitalier Universitaire Vaudois (CH)
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-02-06
- Volume
- 12
- Issue
- 2
- Pages
- e0171168
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5293250
- OpenAlex
- W2586344441
- Cited by
- 38
- References
- 70
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 2 · 2023: 5 · 2022: 3 · 2021: 8 · 2020: 3 · 2019: 7 · 2018: 2 · 2017: 3
- FWCI
- 0.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- Staatssekretariat für Bildung, Forschung und Innovation (2014.0193)
- Ministère de l'Education Nationale, de l'Enseignement Supérieur et de la Recherche
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- statins, heart failure, reduced ejection fraction, sudden cardiac death, all-cause mortality, hospitalization for worsening heart failure, risk of bias, publication bias, small-study effects, trial heterogeneity, cardiovascular risk stratification, secondary prevention, LDL cholesterol lowering, statin tolerability
- MeSH terms
- Cause of Death, Heart Failure, Humans, Stroke Volume, Odds Ratio, Randomized Controlled Trials as Topic, Death, Sudden, Cardiac, Treatment Outcome, Publication Bias, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.